Emotion regulation intervention for depression and healthy individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial investigates the effectiveness of a smartphone-based emotion regulation intervention targeting both positive and negative emotions in individuals with mild to moderate major depressive disorder and healthy controls. Participants will be randomly assigned to either an intervention group, which receives valence-specific strategies for emotion regulation, or a control group that only monitors their emotions. The study aims to explore how beliefs about emotions influence the selection of regulation strategies and to assess improvements in emotion regulation ability and depressive symptoms. Outcome measures will include self-efficacy and the use of emotion regulation strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Online consent for participation
* Adequate proficiency in the German language, encompassing both reading and comprehension skills
* Ownership of a smartphone, compatible with either Android or iOS operating systems, and access to the Internet

For individuals in the clinical group with current depressive disorders:

* Currently meeting the DSM-5 criteria for a mild or moderate major depressive episode, or persistent depressive disorder

Exclusion Criteria:

* Current severe substance use disorder
* Acute suicidality
* Current severe major depressive episode
* Lifetime bipolar disorder
* Lifetime psychotic disorders

For the control group, additional exclusion criteria include:

* Meeting the DSM-5 criteria for a major depressive episode within the last 12 months
* History of severe major depressive episodes
* Recurrent depressive disorder
* History of persistent depressive disorder
* Current treatment (psychotherapy, pharmacotherapy) for depressive symptoms

Where it's running

• Department of Clinical Psychology and Psychotherapy, Institute of Psychology, Heidelberg University
  Heidelberg, Germany Recruiting

Study contacts

• Principal investigator: Ilka Mueller, M.Sc. — Department of Psychology, Heidelberg University
• Study coordinator: Ilka Mueller, M.Sc.
• Email: ilka.mueller@psychologie.uni-heidelberg.de
• Phone: +496221/547362

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brenipatide added to standard care for adults with major depressive disorder

  This study tests whether brenipatide, given alongside standard care, can help delay the return of depressive symptoms in adults with major depressive disorder.

  Recruiting at 47 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 169 other locations · NCT07775300

• Student Precarity and Psychiatry: How Financial Struggles Relate to Depression and Loneliness

  This observational study looks at whether financial hardship and social isolation are linked to depression, suicidal thoughts, and loneliness among French university students.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, IDF · NCT07618208

• Seltorexant (JNJ-42847922) as monotherapy for adults and older adults with major depressive disorder

  This trial will test whether seltorexant works better than a placebo to reduce depressive symptoms in adults and elderly people with major depressive disorder.

  Recruiting at 53 sites Phase 3 Janssen Research & Development, LLC · Bryant, Arkansas and 52 other locations · NCT07573176

• MOCHA: Inpatient Mental Health Care for High-Risk Pregnancy

  This study tests a collaborative mental health program for pregnant or recently postpartum patients hospitalized for medical problems to see if it can be delivered feasibly and acceptably.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07540585

• Brenipatide added to standard antidepressant treatment for adults with major depression

  This trial will see if adding brenipatide to your current antidepressant treatment can delay the return of major depressive symptoms in adults with major depressive disorder.

  Recruiting at 170 sites Phase 3 Eli Lilly and Company · Moorpark, California and 179 other locations · NCT07412756

• Esketamine plus standard care for adolescents with major depressive disorder and acute suicidal thoughts or behavior

  This will test whether adding intranasal esketamine to usual care helps hospitalized adolescents with major depressive disorder and acute suicidal thoughts or behavior feel better faster than a psychoactive placebo plus usual care.

  Recruiting at 49 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 48 other locations · NCT07227454

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.